At the annual roadshow event for pharmaceutical and biotechnology listed companies with the theme of 'New Opportunities in the Pharmaceutical and Biotechnology Industry' held at the Shenzhen Stock Exchange, Wu Shijun, the board secretary of Aier Eye Hospital Group, responded to investors' concerns, saying, 'In the field of ophthalmology, there is a part that has selective demand, such as refractive surgery. The pandemic of the past three years has affected consumer expectations, but we believe that selective demand will only be postponed, not disappear. After the future economic recovery stabilizes, people will still choose to seek medical treatment. Looking at the basic demand for ophthalmology, the demand for eye healthcare among Chinese teenagers is high, and consumers' awareness of eye health is gradually increasing.' Wu Shijun pointed out that according to third-party data, in 2023, China's ophthalmology medical services market is estimated to be approximately 185.5 billion yuan, with the private ophthalmology market accounting for approximately 77.3 billion yuan. (21st Century Business Herald)